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Peroxisome proliferator-activated receptors (PPARα, δ,a n dγ) are ligand-activated transcription factors that regulate a wide
range of cellular processes, including inﬂammation, proliferation, diﬀerentiation, metabolism, and energy homeostasis. All three
PPAR subtypes have been identiﬁed in the central nervous system (CNS) of rodents. While PPARα and PPARγ are expressed in
more restricted areas of the CNS, PPARδ is ubiquitously expressed and is the predominant subtype. Although data regarding
PPARδ are limited, studies have demonstrated that administration of PPARδ agonists confers neuroprotection following various
acute and chronic injuries to the CNS, such as stroke, multiple sclerosis, and Alzheimer’s disease. The antioxidant and anti-
inﬂammatory properties of PPARδ agonists are thought to underly their neuroprotective eﬃcacy. This review will focus on the
putative neuroprotective beneﬁts of therapeutically targeting PPARδ in the CNS, and speciﬁcally, highlight the antioxidant and
anti-inﬂammatory functions of PPARδ agonists.
1.Introduction
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear hormone receptor superfamily.
Three closely related subtypes have been identiﬁed—PPARα
(NR1C1), PPARδ (NR1C2, PPARβ), and PPARγ (NR1C3)
[1]. They are ligand-activated transcription factors that
heterodimerize with the retinoid X receptor to regulate
transcription [2, 3] .E a c hP P A Rs u b t y p ei se n c o d e db ya
diﬀerent gene and has a unique tissue distribution. PPARs
possess a high degree of structural homology and share the
same DNA response element, termed the PPAR response
element (PPRE). PPREs consist of an AGGTCA hexameric
directrepeatseparatedbyoneortwonucleotides[4].Despite
sharing PPREs, the three subtypes have both similar and
diﬀerent functions. The speciﬁcity of their functions appears
to depend on their diﬀerential (i) tissue expression, (ii)
ligand speciﬁcity, (iii) A/B-domain, (iv) posttranslational
modiﬁcations, (v) aﬃnity for cofactors, (vi) aﬃnity for
individual PPREs, and (vii) nongenomic actions [5].
A common function of the PPAR subtypes is suppressing
oxidative stress and inﬂammatory processes [6]. Although
the CNS was once thought to be immune privileged due
to the protection of the BBB, numerous studies have dem-
onstrated that inﬂammation does occur in the brain and
spinal cord and is associated with many neurodegenerative
disorders [7]. These ﬁndings provided the original rationale
for assessing the neuroprotective eﬃcacy of PPAR agonists
in a variety of CNS disorders. The neuroprotective eﬃcacy
of PPARα and PPARγ agonists has been reviewed previously
[8–10].
Despite being the predominant subtype in the CNS [11],
data regarding the neuroprotective eﬃcacy of PPARδ ago-
nistsarelimitedcomparedtoPPARαorPPARγ agonists.This
likelyreﬂectsthefactthatPPARδ-speciﬁcagonistsandantag-
onists have only recently become available. Several studies
have used the synthetic PPARδ-speciﬁc agonists L-165041,
L-160,043, GW0742, or GW501516 to explore the functional
activities of the receptor [12–15]. Recent studies assessing2 PPAR Research
the neuroprotective eﬃcacy of synthetic PPARδ agonists
indicate that they may ameliorate clinical symptoms and
reduce the severity of a variety of acute and chronic CNS
pathologies, in large part, by modulation of oxidative stress
and inﬂammatory responses associated with the diseases.
Recent reports suggest that PPARδ may have additional
protective eﬀects against the progression of CNS disorders,
such as promoting cell survival [12, 13, 16]. To date,
the neuroprotective beneﬁts of PPARδ agonists have been
observed in models of stroke, multiple sclerosis, Alzheimer’s
disease, Parkinson’s disease, radiation-induced brain injury,
and spinal cord injury [12, 17–23].
2. PPARδ Expressionin the CNS
The expression of PPARδ h a sb e e ne x a m i n e di nm a n yr o d e n t
tissues, including the CNS. The receptor is thought to be
ubiquitously expressed in the adult rodent brain and spinal
cord [11, 24–26]. In rats, PPARδ begins to be expressed
at midgestation, reaching peak expression in all neural
tissues in the late stage embryonic brain, suggesting that
it may play a role in cell diﬀerentiation in the CNS [27].
In situ hybridization and immunolocalization studies have
demonstrated that high levels of PPARδ are found in the
hippocampus, telencephalic cortex, and the cerebellar cortex
of rats [11, 27, 28]. Other studies in the rat brain indicate
that PPARδ mRNA is highly expressed in the thalamic nuclei
[25]. In the rat spinal cord, PPARδ is the most abundant
PPAR subtype; it is expressed in every cell layer and highly
expressed in the lamina II and lamina IX layers [11]. Rat
brainendothelialcellsalsoexpressPPARδ mRNA,suggesting
a possible role in blood-brain barrier (BBB) maintenance
[29]. PPARδ is also widely expressed in the mouse brain,
with high levels in the entorhinal cortex, hypothalamus,
hippocampus, and corpus callosum. Localization studies
identiﬁed PPARδ mRNA and protein in mouse neurons and
oligodendrocytes, but not in astrocytes [26]. However, in cell
culture, PPARδ expression has been documented in mouse
and rat cortical astrocytes as well as in rat cerebral astrocytes
[30, 31]. Results from our own laboratory demonstrate that
the receptor is also expressed in microglia. Taken together,
PPARδ expression has been observed in all the major cell
types within the CNS, including astrocytes, endothelial cells,
microglia, neurons, and oligodendrocytes.
3. Stroke-Induced BrainInjury
Strokes are often caused by a blockage of blood ﬂow in the
brain, referred to as ischemia, which results in a shortage
of oxygen to the brain. Vascular degradation after cerebral
ischemia leads to BBB disruption and neuronal loss. Of the
three PPAR isotypes, PPARδ is the highest expressed in the
brain’s parenchyma and cerebral vasculature, and increasing
evidence suggests that PPARδ may protect against ischemic
insults [13]. This was ﬁrst highlighted in PPARδ-null mice,
which compared to WT mice, had a signiﬁcant increase
in infarct size after focal cerebral ischemia [17, 18]. The
diﬀerence in infarct size was detected as early as 30 min after
induction of ischemia, suggesting that PPARδ plays an early
role in protection [17]. Following middle cerebral artery
occlusion (MCAO), increased cerebrovascular permeability
and infarct size were detected in mice with speciﬁc deletion
of PPARδ in vascular smooth muscle cells (VSMCs) [13].
Additionally, PPARδ agonists appear to be protective after
cerebral ischemia; rats given infusions of L-165041 or
GW501516 had signiﬁcantly attenuated ischemic damage
24h after MCAO [12]. The mechanisms underlying the
protective eﬀect of PPARδ, however, are unclear. Potential
protective eﬀects include (i) modulating oxidative stress
and proinﬂammatory responses, (ii) maintaining matrix-cell
adhesions, and (iii) promoting cell survival.
The enhanced oxidative stress and inﬂammatory
responses in an ischemic brain are thought to contribute
to neuronal death. The antioxidant and anti-inﬂammatory
actions of PPARδ agonists have been observed in a variety
of cell types, including astrocytes and microglia [32–35]. In
particular, PPARδ can activate transcription of antioxidant
genes, including catalase and superoxide dismutase (SOD)
[36–38]. PPARδ can also control gene transcription
independent of binding to PPREs. Transrepression is
thought to underlie many of the anti-inﬂammatory eﬀects
of PPARδ.P P A R δ can exert transrepression by directly
interacting with nuclear factor-κB( N F - κB), thereby
inhibiting activation of the proinﬂammatory transcription
factor [38]. In addition, PPARδ exerts transrepression in
macrophages by relocating the transcriptional repressor
B-cell lymphoma protein 6 (Bcl-6) from PPARδ to the
promoter regions of proinﬂammatory genes, including
the vascular cell adhesion molecule-1 (VCAM-1) and the
monocyte chemoattractant protein-1 (MCP-1) [39–41].
It is possible that modulation of these processes con-
tributes to the protective eﬀect of PPARδ after cerebral
ischemia. In an in vivo model of MCAO, for example,
there was an increase in the lipid peroxidation marker,
malondialdehyde, and a decrease in the levels of the antiox-
idant, glutathione, and the antioxidant enzyme, manganese
(Mn)SOD, in PPARδ-null mice compared to WT mice. This
suggests that there is increased oxidative stress in PPARδ-
null mice following cerebral ischemia [18]. Additionally,
mice with PPARδ speciﬁcally deleted in their VSMCs had
a signiﬁcant increase in proinﬂammatory mediators in
their brain 24h after MCAO. This included an increase
in the mRNA levels of interleukin-1 beta (IL-1β), IL-6,
intercellular adhesion molecule-1 (ICAM-1), and MCP-1
[13]. Pioglitazone, a PPARγ agonist, has been shown to
confer neuroprotection following MCAO. This is thought
to occur, in part, by activation of PPARδ, which enhances
production of the IL-1 receptor antagonist (IL-1Ra). IL-1Ra
promotes neuroprotection by competing with binding of IL-
1β to IL-1R1; consequently, this represses receptor signaling
and reduces inﬂammatory responses following ischemia
[42].
The pathogenesis of cerebral ischemia also involves the
breakdown of matrix-cell adhesions, which results in the
disruption of the BBB and ultimately neuronal death and
brain damage. PPARδ may regulate these responses by
decreasing activity of matrix metalloproteinases (MMPs),PPAR Research 3
enzymes that degrade structural proteins in the extracel-
lular matrix and that have been implicated in ischemia-
induced parenchymal and vascular damage. In particular,
treatment of VSMCs with the PPARδ agonist, GW501516,
reducedMMP-9enzymaticactivity24hafteroxygen-glucose
deprivation (OGD). Furthermore, VSMC-selective PPARδ
knockout mice exhibited increased MMP-9 expression fol-
lowing MCAO, and inhibition of MMP-9 using shRNA
reduced infarct size and vascular permeability in these mice
[13]. More studies, however, are needed to understand the
mechanism by which PPARδ regulates MMP-9 expression.
PPARδ m a ya l s op r o m o t ec e l ls u r v i v a la f t e ri s c h e m i c
insults. In particular, GW501516 signiﬁcantly reduced cere-
bralvascularendothelial celldegenerationin anOGDmouse
model. GW501516 protected against vascular cell death by
inhibiting expression of miR-15a, which directly regulates
the antiapoptotic protein Bcl-2. This resulted in increased
Bcl-2 protein expression, reduced Golgi fragmentation, and
decreased caspase-3 activity, which in turn reduced cere-
brovascular permeability and infarct volume in vivo [43].
Althoughnottestedwithrespecttoprotectionagainststroke-
induced injury, PPARδ has been shown to promote survival
of neurons under stress conditions. Speciﬁcally, L-165041 or
GW501516 signiﬁcantly reduced SH-SY5Y cell death after
exposureto(i)thapsigargin,anendoplasmicreticulumCa2+
ATPase inhibitor; (ii) 1-methyl-4-pheylpyridinium (MPP+),
a dopaminergic neurotoxin; or (iii) staurosporine, a protein
kinase inhibitor. The eﬀect on viability may be due to
inhibition of apoptosis, as both agonists could signiﬁcantly
attenuate caspase-3 and caspase-7 activity in cells treated
with one of the three cytotoxins [12]. GW0742 has also been
shown to be neuroprotective in primary cultures of rat cere-
bellargranuleneuronsexposedtolow-KClmedia.Prolonged
exposure of primary cultures to GW0742, however, induced
apoptotic cell death [44]. Future studies should examine if,
similar to vascular endothelial cells, PPARδ agonists can also
promote neuronal survival after ischemic insults.
4. MultipleSclerosis
Multiplesclerosis(MS)isanautoimmunediseasethatresults
in the expansion of pathogenic T cells speciﬁc for myelin au-
toantigens [45]. The disease manifests in the destruction of
myelin sheaths and the inﬂammatory activation of glial cells
[46]. Experimental autoimmune encephalomyelitis (EAE),
in which mice are immunized with the encephalitogenic
myelin oligodendrocyte glycoprotein (MOG) peptide, is
used as a model of MS [47, 48]. The potential role of
PPARδ in demyelinating diseases was ﬁrst proposed in a
model that attempted to explain the detrimental eﬀects of
inﬂammatory mediators on myelin synthesis. Speciﬁcally,
tumor necrosis factor alpha (TNF-α), a cytokine implicated
in demyelinating pathologies, was demonstrated to attenuate
PPARδ expression in OPCs and, concurrently, decrease very
long-chainfattyacid(VLCFA)β-oxidation.Thehypothetical
model proposed that decreased PPARδ expression would
lead to VLCFA accumulation, which would induce cytotoxic
eﬀects and demyelination. PPARδ agonists, therefore, were
postulated to be beneﬁcial for MS-aﬀected individuals [49].
GW0742 was the ﬁrst PPARδ agonist to show beneﬁcial
eﬀects in a mouse model of EAE [14, 20]. The eﬀects of
GW0742 were greater when administered to mice during
disease progression, rather than when given at the time
of MOG administration. Speciﬁcally, GW0742 reduced the
emergence of new cortical lesions, increased proteolipid
protein (PLP) mRNA levels, and reduced IL-1β levels [14].
The levels of interferon-gamma (IFNγ)w e r en o ta l t e r e db y
GW0742, which is in contrast to observations in mouse
and human immune cells that demonstrate GW0742 can
inhibitproductionofIFN-γ [14,20].Theprotectiveeﬀectsof
GW0742 are likely mediated by reducing inﬂammatory cell
activation [14].
Research indicates that GW501516 and L-165041 are
also eﬀective at ameliorating EAE. In mice, the attenuation
of EAE by GW501516 or L-165041 was associated with
decreased expression of the proinﬂammatory cytokines,
IL-2 and IL-23, and increased expression of the anti-
inﬂammatory cytokines, IL-4 and IL-10. Reduced produc-
tion of IFNγ and IL-17 by T helper type 1 (Th1) and
Th17 cells was also observed in EAE mice treated with
GW501516 or L-165041 [50]. In accord with these ﬁndings,
PPARδ-null mice with EAE had impaired Th1/Th17 and
Th2/Treg responses, which may contribute to the extended
recovery time in PPARδ-null mice compared to WT mice.
The prolonged EAE in PPARδ-null mice was associated
with sustained levels of IFNγ, IL-17, IL-12p35, and IL-
12p40, consistent with the hypothesis that PPARδ regulates
inﬂammatory responses associated with EAE [19].
PPARδ-null mice with EAE also exhibited a severe
inﬂammatory response in their spinal cord—they had a
higher frequency of CD4+ cells that had an accumulation
of IFN-γ or IL-17A compared to WT mice [20]. Intrigu-
ingly, PPARδ also appears to play a protective role in
the spinal cords of steroid-receptor-coactivator-3-(SRC-3-)
null mice with EAE. SRC-3-null mice had a signiﬁcantly
reduced severity of EAE that was associated with diminished
inﬂammatory responses and decreased demyelination. The
attenuatedEAEsymptomsinSRC-3-nullmicearethoughtto
occur via upregulation of PPARδ. SRC-3-null mice displayed
decreased expression of the proinﬂammatory markers, TNF-
α,I F N - γ, CCL2, CCL3, CCL5, and CXCL10, and increased
expression of the anti-inﬂammatory markers, IL-10 and
opsonins. Myelin genes—myelin basic protein (MBP) and
PLP—were also signiﬁcantly higher in SRC-3-null mice,
which may be a result of increased PPARδ expression [51].
In SRC-3 mice, PPARδ expression is thought to alter-
natively activate microglia from the proinﬂammatory M1
phenotype to the anti-inﬂammatory M2 phenotype. In
particular,therewasacorrelationbetweenPPARδ expression
in SRC-3-null mice and ramiﬁed microglia that expressed
Ym1/2 and Mrc1, phenotypic markers for alternative activa-
tion. Interestingly, PPARδ activation has been shown to con-
trol the alternative activation of adipose tissue macrophages
(ATMs) and Kupﬀer cells, hepatic macrophages [52, 53].
In the white adipose tissue of PPARδ-null mice, genes of
alternatively activated macrophages, Clec7a, Retnla, Tgfb1,4 PPAR Research
Jag1, and Mrc1, were reduced. The alternative activation of
Kupﬀer cells was also decreased in PPARδ-null mice, as
assessed by reduced expression of Arg1, Clec7a, Jag1,
Pdcd1lg2, and Chia [53]. Reduced alternative activation of
ATMs and Kupﬀer cells in PPARδ-null mice led to impaired
glucose tolerance and insulin resistance [52, 53]. Whether
PPARδ agonists can alternatively activate microglia remains
to be determined.
To further examine the mechanisms by which PPARδ
is protective in models of EAE, studies have used in vitro
models of aggregating brain cells. GW501516 was eﬀective
at reducing IFN-γ- or lipopolysaccharide- (LPS-) induced
TNF-α or inducible nitric oxide synthase (iNOS) mRNA
levels; however, it increased IL-6 mRNA expression. In
the presence of anti-MOG, a demyelinating antibody,
GW501516 was unable to prevent decreases in MBP [54].
These results further suggest that in models of EAE, the
protective eﬀects of PPARδ agonists may be due to their anti-
inﬂammatory properties rather than their eﬀects on myelin
genes or oligodendrocytes. Collectively, the ﬁndings above
indicate that PPARδ agonists ameliorate the inﬂammatory
responses in EAE and may represent therapeutic avenues to
ameliorate MS progression.
5. Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by neuronal degeneration and progressive
cognitive impairment [55]. While the pathogenesis of AD is
not fully understood, AD patients exhibit an accumula-
tion of amyloid plaques formed by oligomerization of the
amyloidogenic peptides, Aβ 1–42 and Aβ 1–40, and neu-
roﬁbrillary tangles formed by tau protein. These plaques
and tangles are thought to contribute to neurodegeneration
[56]. Inﬂammatory cytokines may lead to an increase in Aβ
peptides, thereby contributing to the progression of AD. The
neurotransmitter noradrenaline (NA) can protect neurons
from various inﬂammatory stimuli, including exposure to
Aβ peptides. This is thought to occur, in part, by activation
of PPARδ. In particular, in primary cultures of rat cortical
neurons,AβpeptidesinducedcelldeathasmeasuredbyLDH
release. The ability of NA to prevent Aβ peptide-induced cell
death was decreased in the presence of GW9662, a PPAR
antagonist. Moreover, GW0742 blocked cell death to the
same degree as NA, as measured by LDH release and Fluoro-
Jade B staining [21].
Further supporting the possible beneﬁts of targeting
PPARδ in the treatment of AD, administration of GW0742
signiﬁcantly reduced amyloid plaque burden in the subicu-
lum of 5xFAD mice. These mice overexpress the amyloid
precursor protein and presenilin 1, display plaques and
inﬂammation, and develop neuronal damage and cognitive
impairment. Interestingly, the decrease in amyloid burden in
GW0742 treated 5xFAD mice was associated with increased
expression of neprilysin, an amyloid-degrading enzyme.
Furthermore, GW0742 could activate a neprilysin promoter
driving luciferase expression in vitro. GW0742 also led to
a decrease in astrocyte activation in the 5xFAD mice, as
assessed by GFAP staining [22].
Streptozotocin (STZ) administered to mice intracere-
brally depletes brain insulin levels and induces progressive
neurodegeneration that corresponds to the clinical symp-
toms of AD. Impairments in insulin and insulin-like growth
factor signaling are observed in AD brains and these abnor-
malities increase concomitantly with dementia [57, 58].
Treatment with the PPARδ agonist, L-160,043, prevented
STZ-induced neurodegeneration and ameliorated cognitive
impairment as evaluated by the Morris Water Maze task.
These eﬀects of L-160,043 were attributed to (i) increased
insulin receptor signaling, (ii) reduced tau phosphorylation,
(iii) increased choline acetyltransferase, and (iv) attenuated
inﬂammationandoxidativestress.Consistentwiththeeﬀects
of GW0742 described above, L-160,043 reduced levels of
GFAP. Furthermore, L-160,043 reduced immunoreactivity
of the oxidative stress markers, 8-hydroxyguanosine (8-
OHdG) and 4-hydroxynonenal (HNE), relative to STZ-
treated animals [15]. Elevated levels of 8-OHdG and HNE
have been detected in AD brains [59, 60]. This suggests
that PPARδ agonists may be eﬃcacious antioxidant agents to
ameliorate oxidative stress associated with AD. Interestingly,
the actions of L-160,043 were more pronounced than the
PPARα agonist, GW7647, or partial PPARγ agonist, F-L-
Leu [15]. It is important to note that the PPARδ agonist
was administered the same day as STZ. Future studies
should assess whether PPARδ activation at later stages of AD
progression can also halt AD development.
6. Parkinson’sDisease
PPARδ agonists may exert therapeutic beneﬁts in patients
with Parkinson’s disease (PD), a neurodegenerative dis-
order characterized by loss of dopaminergic neurons in
the substantia nigra. Progression of PD has been at-
tributed to reactive oxygen species (ROS) and oxidized
dopamine, which are toxic to dopaminergic neurons [61].
This disease manifests itself in motor dysfunctions and
tremors. The synthetic opiate 1-methyl-4-phenyl-1,2,3,6-
tetrahydrodropyridine(MPTP)inducesPDindrug-addicted
individuals. In mice, administration of GW501516 or L-
165041 48h before the ﬁrst injection of MPTP signiﬁ-
cantly ameliorated depletion of striatal dopamine and its
metabolites. As mentioned above, these PPARδ agonists also
protected human neuroblastoma cells, SH-SY5Y, from cell
death induced by the dopaminergic neurotoxin MPP+. This
protection was associated with a signiﬁcant reduction of
caspase-3 and may contribute to the neuroprotective eﬃcacy
of GW501516 and L-165041 in experimental models of PD
[12] .T h ep r o t e c t i v er o l eo fP P A R δ in PD has not been
adequatelyexplored,anditisunclearif,similartothePPARγ
agonistpioglitazone,PPARδ agonistscanmodulateoxidative
stress and inﬂammatory processes associated with PD. In
particular, in a mouse model of PD, pioglitazone prevented
MPTP-induced glial cell activation and loss of dopaminergic
neurons. Mechanistically, neuronal death was prevented by
inhibiting activation of the proinﬂammatory transcriptionPPAR Research 5
factor NF-κB by (i) increasing Iκ-Bα expression and (ii)
inhibiting nuclear translocation of p65. Pioglitazone also
decreased the number of GFAP and iNOS positive cells in
both the striatum and substantia nigra pars compacta [62].
7.Astrogliosis
Many CNS disorders are associated with astrogliosis. During
astrogliosis, astrocytes are thought to increase produc-
tion of proinﬂammatory mediators, such as arachidonic
acid [63, 64]. Arachidonic acid, which is a substrate for
cyclooxygenase-1 (Cox-1) and Cox-2, is released by phos-
pholipase A2 (PLA2). PLA2 and Cox-2 have been associated
with neurodegenerative diseases [65, 66]. Interestingly, both
secretory PLA2 (sPLA2) and cytosolic PLA2 (cPLA2)c o n t a i n
a PPRE in their promoters. PPARδ expression appears
to be abundant in immature cultures of primary rodent
astrocytes [30]. In primary rat brain astrocytes, pretreatment
of astrocytes with L-165041 attenuated LPS-induced sPLA2
expression, while astrocytes treated simultaneously with L-
165041 and LPS displayed increased cPLA2 expression and
had no change in sPLA2 expression. As the authors noted,
LPS stimulates NF-κB and activator protein-1 (AP-1), which
PPARs have been shown to transrepress. It is possible that
in this model LPS-induced activation of NF-κB and AP-
1 is acting to transrepress PPARδ [35]. Furthermore, LPS-
induced Cox-2 expression in rat primary astrocytes may be
modulated, in part, by PPARδ. In particular, rosiglitazone,
aP P A R γ agonist, increased PPARδ expression in cortical
astrocytes and led to increased Cox-2 expression. On the
other hand, GW7647, a PPARα agonist, reduced PPARδ
levels and decreased LPS-induced Cox-2 expression [67].
Theseresultsaresurprisinggiventhatstudieslargelyfocuson
the antioxidant and anti-inﬂammatory properties of PPARs.
8. Radiation-InducedBrain Injury
Fractionated partial or whole-brain irradiation (fWBI) is
often required to treat both primary and metastatic brain
cancer. Radiation-induced brain injury, including progres-
sive cognitive impairment, however, can signiﬁcantly aﬀect
the well-being of the approximately 200,000 patients who
receive these treatments each year [68, 69]. Recent reports
indicate that the pathogenesis of radiation-induced brain
injury may be caused, in part, by chronic oxidative stress
and inﬂammatory responses, as well as increased microglial
activation in the brain [70–72]. Microglia, which are termed
the macrophages of the brain, are considered to be one of the
key mediators of neuroinﬂammation [73–75]. Data suggest
that irradiating microglial cells in vitro leads to an increase
in a variety of proinﬂammatory mediators, including the
cytokines, TNF-α and IL-1β, and the chemokines, MCP-1
andICAM-1[76–78].Studiesperformedinvivoindicatethat
there is an increase in proinﬂammatory mediators within
hours of irradiating the rodent brain [76, 79]. To date,
studies in rodents have demonstrated that administration
of anti-inﬂammatory drugs can decrease radiation-induced
microglial activation [80, 81]. These ﬁndings provide a
strong rationale for investigating whether administration
of PPARδ agonists can confer neuroprotection following
irradiation.
Ongoing studies in our laboratory are investigating the
abilityofPPARδ tomodulateradiation-inducedbraininjury.
Incubating BV-2 murine microglial cells with the PPARδ
agonist, L-165041, is eﬀective at modulating radiation-
induced injury, including inhibiting the radiation-induced
increase in (i) intracellular ROS generation, (ii) Cox-
2, iNOS and MCP-1 expression, (iii) IL-1β and TNF-
α message levels, and (iv) NF-κB and AP-1 activation
(unpublished results). These observations demonstrate the
important antioxidant and anti-inﬂammatory actions of
PPARδ agonists in microglial cells following irradiation and
are similar to previous ﬁndings indicating that the PPARα
agonists, GW7647 and fenoﬁbrate, can inhibit radiation-
induced inﬂammatory markers in BV-2 cells [82].
Our laboratory has also assessed the anti-inﬂammatory
actions of PPARδ following irradiation in vivo.O n ew e e k
following a single dose of 10Gy 137Cs γ WBI, young adult
male C57Bl/6 mice exhibited a signiﬁcant increase in the
number of activated microglia (CD68+ cells) in the dentate
gyrus (DG). GW0742 administered prior to, during, and
after WBI prevented this radiation-induced increase in
activated microglia. Interestingly, radiation did not induce
an increase in activated microglia in the DG of PPARδ-
null mice at one week or two months after WBI. These
results suggest that PPARδ deﬁciency leads to an inhibition
ofmicroglialactivation(unpublishedresults).Theseﬁndings
are surprising and quite diﬀerent from those observed in
PPARα-null mice, where PPARα deﬁciency resulted in a
sustained increase in activated microglia seen at one week
and two months after WBI [81]. This indicates that the eﬀect
of PPAR deﬁciency is subtype-dependent.
Although PPARδ-null mice do not show a radiation-
induced microglial response, they may display an astro-
cytic response. Of note, PPARδ-null mice express increased
mRNA levels of GFAP, a marker of astrocytes, compared to
WT mice. Additionally, while WBI reduced the number of
astrocytes, GFAP+ cells, two months after irradiation in WT
mice, there was no apparent decrease in the number of astro-
cytesintheirradiatedPPARδ-nullmice.Whiletheseﬁndings
are preliminary, they do suggest that PPARδ may modulate
the radiation response of the astrocyte (unpublished results).
Although studies have not examined if PPARδ ago-
nists can modulate radiation-induced cognitive impairment,
data demonstrate that PPARγ can ameliorate or prevent
radiation-induced cognitive decline. In particular, pioglita-
zone ameliorated radiation-induced cognitive impairment
when administered prior to, during, and for 4 or 54 weeks
after fWBI of young adult male rats [83]. While these results
are promising, there are concerns with using pioglitazone
in the clinic, including an increased risk of (i) weight
gain and (ii) myocardial infarctions [84]. It is important
to investigate if, similar to PPARγ,P P A R δ can modulate
radiation-induced cognitive impairment. Since PPARδ is the
primary subtype in the CNS, it is possible that PPARδ
agonists can mediate a more pronounced antioxidant and
anti-inﬂammatory response in the brain.6 PPAR Research
Table 1: The neuroprotective beneﬁts of PPARδ agonists.
CNS disorder PPARδ agonist Neuroprotective beneﬁts
Stroke GW501516
Signiﬁcantly attenuated the cortical infarct area following
MCAO-induced ischemic damage in rats [12]
Reduced OGD-induced MMP-9 enzymatic activity in mice [13]
Protected against vascular endothelial cell death by inhibiting expression
of miR-15a, which increased Bcl-2 expression, reduced golgi
fragmentation, and decreased caspase-3 activity [43]
L-165041 Signiﬁcantly attenuated the cortical infarct area following
MCAO-induced ischemic damage in rats [12]
Multiple sclerosis
GW0742 Reduced emergence of new cortical lesions, increased PLP mRNA, and
reduced IL-1β expression in mice immunized with MOG [14]
GW501516
Reduced IL-1, IL-23, IFNγ, and IL-17 and increased IL-4 and IL-10 in
mice immunized with MOG [50]
Reduced LPS-induced TNF-α and iNOS mRNA in aggregating brain
cells [54]
L-165041 Reduced IL-1, IL-23, IFNγ, and IL-17 and increased IL-4 and IL-10 in
mice immunized with MOG [50]
Alzheimer’s disease
GW0742
Blocked Aβ peptide-induced cell death, as measured by LDH release and
Fluorojade B staining, in primary cultures of rat cortical neurons [21]
Decreased amyloid burden, increased neprilysin expression, and
decreased GFAP expression in 5xFAD mice [22]
L-160,043
Prevented STZ-induced neurodegeneration and cognitive impairment
in rats. This was associated with reduced tau phosphorylation, increased
choline acetyltransferase, attenuated 8-OHdG and HNE, and reduced
GFAP expression [15]
Parkinson’s disease
GW501516
Ameliorated MPTP-induced depletion of striatal dopamine and its
metabolites in mice [12]
Reduced Caspase-3 and protected SH-SY5Y cells from MPP+-induced
cell death [12]
L-165041
Ameliorated MPTP-induced depletion of striatal dopamine and its
metabolites in mice [12]
Reduced Caspase-3 and protected SH-SY5Y cells from MPP+-induced
cell death [12]
Radiation-induced brain injury
GW0742 Prevented microglial activation (CD68+ cells) in mice irradiated with a
single dose of 10Gy (unpublished)
L-165041
Prevented intracellular ROS generation, Cox-2, iNOS, and MCP-1
expression, IL-1β and TNF-α mRNA, and NF-κB, and AP-1 activation in
BV-2 cells irradiated with 10Gy (unpublished)
Spinal cord injury GW0742
Improved motor function of mice and reduced TNF-α,I L - 1 β, and iNOS
expression, NF-κB activation, neutrophil inﬁltration, nitrotyrosine and
lipid peroxidation, FasL expression, and TUNEL staining [23]
Reduced Cox-2, p-p38 MAPK, and p-c-jun expression, and NF-κB
activation in murine spinal cord slices [88]
9. Spinal Cord Injury
Spinal cord injury (SCI) is associated with altered con-
duction of axons and motor dysfunction due to oligoden-
drocyte and neuronal cell death [85]. SCI is accompanied
by inﬂammation and edema, which results in inﬁltration
of inﬂammatory cells, release of proinﬂammatory factors,
vascular permeability, and ultimately necrosis [86, 87].
Data suggest that PPARδ can modulate these responses.
Administration of GW0742 to mice after SCI signiﬁcantly
improved their motor function. The PPARδ antagonist,
GSK0660, blocked the eﬀect of GW0742 on motor function
suggesting that the protective eﬀects of the agonists are
dependent on activation of the PPARδ receptor. The eﬀects
ofGW0742wereassociatedwithreducedoxidativestressand
proinﬂammatory responses in the spinal cord. This included
ar e d u c t i o ni n( i )T N F - α,I L - 1 β, and iNOS expression, (ii)
NF-κB activation, (iii) neutrophil inﬁltration, (iv) nitroty-
rosine and lipid peroxidation, (v) FasL expression, and (vi)
TUNEL staining [23]. In accord with these ﬁndings, data
demonstrate that GW0742 administered 1 hour prior to SCI
reduced cell death and inﬂammation in cultured murinePPAR Research 7
spinal cord slices. The reduction in inﬂammation included
decreased (i) Cox-2 expression and (ii) p38 MAPK, c-Jun N-
terminal kinase, and NF-κBa c t i v a t i o n[ 88].
It has also been proposed that PPARδ attenuates SCI by
promoting oligodendrocyte precursor cell (OPC) prolifera-
tion and diﬀerentiation following injury. Studies have shown
that OPCs accumulate at SCI sites, likely as an attempt to
regenerate the damaged axons [89]. Following SCI in rats,
PPARδ positive cells increased in the white matter along
the lesion border for up to two weeks. Double-labeling
experiments indicated there was an increase in PPARδ in
NG2 positive cells, potential OPCs, and PPARδ positive CC1
cells, oligodendrocytes [90]. Given the temporal and spatial
expression of PPARδ after SCI, it is possible that it can
regulate oligodendrogenesis after injury.
10. Summary
Taken together, the ﬁndings described above indicate that
PPARδ agonistsshowpromiseaspotentialtherapeuticagents
for a variety of CNS pathologies, including stroke, MS,
AD, PD, radiation-induced brain injury, and SCI. The
neuroprotective eﬃcacy of PPARδ agonists are, in large part,
mediated by modulating oxidative stress and inﬂammatory
processes;theneuroprotectivebeneﬁtsofPPARδ agonistsare
summarized in Table 1. Future studies using in vitro and in
vivo approaches should further address the mechanisms by
which PPARδ exerts its antioxidant and anti-inﬂammatory
eﬀects and help establish the foundations for future clinical
applications of PPARδ agonists.
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